184 related articles for article (PubMed ID: 12432546)
1. Interference with TGF-beta1 and -beta3 in tumor stroma lowers tumor interstitial fluid pressure independently of growth in experimental carcinoma.
Lammerts E; Roswall P; Sundberg C; Gotwals PJ; Koteliansky VE; Reed RK; Heldin NE; Rubin K
Int J Cancer; 2002 Dec; 102(5):453-62. PubMed ID: 12432546
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of cell cycle arrest in response to TGF-beta in progestin-dependent and -independent growth of mammary tumors.
Salatino M; Labriola L; Schillaci R; Charreau EH; Elizalde PV
Exp Cell Res; 2001 Apr; 265(1):152-66. PubMed ID: 11281653
[TBL] [Abstract][Full Text] [Related]
3. Hyaluronan content in experimental carcinoma is not correlated to interstitial fluid pressure.
Jacobson A; Salnikov A; Lammerts E; Roswall P; Sundberg C; Heldin P; Rubin K; Heldin NE
Biochem Biophys Res Commun; 2003 Jun; 305(4):1017-23. PubMed ID: 12767932
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of transforming growth factor (TGF) beta1 type II receptor restores TGF-beta1 sensitivity and signaling in human prostate cancer cells.
Guo Y; Kyprianou N
Cell Growth Differ; 1998 Feb; 9(2):185-93. PubMed ID: 9486855
[TBL] [Abstract][Full Text] [Related]
5. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.
Subramanian G; Schwarz RE; Higgins L; McEnroe G; Chakravarty S; Dugar S; Reiss M
Cancer Res; 2004 Aug; 64(15):5200-11. PubMed ID: 15289325
[TBL] [Abstract][Full Text] [Related]
6. Restoration of transforming growth factor beta signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis.
Guo Y; Kyprianou N
Cancer Res; 1999 Mar; 59(6):1366-71. PubMed ID: 10096572
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of transforming growth factor on cell cycle regulatory molecules in human myeloid leukemia cells.
Hu X; Zhang X; Zhong Q; Fisher AB; Bryington M; Zuckerman KS
Oncogene; 2001 Oct; 20(47):6840-50. PubMed ID: 11687963
[TBL] [Abstract][Full Text] [Related]
8. BMP-7-induced cell cycle arrest of anaplastic thyroid carcinoma cells via p21(CIP1) and p27(KIP1).
Franzén A ; Heldin NE
Biochem Biophys Res Commun; 2001 Jul; 285(3):773-81. PubMed ID: 11453659
[TBL] [Abstract][Full Text] [Related]
9. Fibroblast growth factor-2 mediates transforming growth factor-beta action in prostate cancer reactive stroma.
Yang F; Strand DW; Rowley DR
Oncogene; 2008 Jan; 27(4):450-9. PubMed ID: 17637743
[TBL] [Abstract][Full Text] [Related]
10. Expression of transforming growth factor-beta1 and transforming growth factor-beta Type-II receptor mRNA in papillary thyroid carcinoma.
Matoba H; Sugano S; Yamaguchi N; Miyachi Y
Horm Metab Res; 1998 Oct; 30(10):624-8. PubMed ID: 9851670
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of transforming growth factor beta type I receptor abolishes malignant phenotype of a rat bladder carcinoma cell line.
Okamoto M; Oyasu R
Cell Growth Differ; 1997 Aug; 8(8):921-6. PubMed ID: 9269901
[TBL] [Abstract][Full Text] [Related]
12. TGF-beta1 acts as a tumor suppressor of human malignant keratinocytes independently of Smad 4 expression and ligand-induced G(1) arrest.
Paterson IC; Davies M; Stone A; Huntley S; Smith E; Pring M; Eveson JW; Robinson CM; Parkinson EK; Prime SS
Oncogene; 2002 Feb; 21(10):1616-24. PubMed ID: 11896591
[TBL] [Abstract][Full Text] [Related]
13. Immuno-PET of undifferentiated thyroid carcinoma with radioiodine-labelled antibody cMAb U36: application to antibody tumour uptake studies.
Fortin MA; Salnikov AV; Nestor M; Heldin NE; Rubin K; Lundqvist H
Eur J Nucl Med Mol Imaging; 2007 Sep; 34(9):1376-87. PubMed ID: 17277931
[TBL] [Abstract][Full Text] [Related]
14. TGF-beta 1 induces the cyclin-dependent kinase inhibitor p27Kip1 mRNA and protein in murine B cells.
Kamesaki H; Nishizawa K; Michaud GY; Cossman J; Kiyono T
J Immunol; 1998 Jan; 160(2):770-7. PubMed ID: 9551912
[TBL] [Abstract][Full Text] [Related]
15. Blockade of tumor cell transforming growth factor-betas enhances cell cycle progression and sensitizes human breast carcinoma cells to cytotoxic chemotherapy.
Ohmori T; Yang JL; Price JO; Arteaga CL
Exp Cell Res; 1998 Dec; 245(2):350-9. PubMed ID: 9851876
[TBL] [Abstract][Full Text] [Related]
16. Transforming growth factor-beta and p27 expression in pituitary cells.
Qian X; Jin L; Grande JP; Lloyd RV
Endocrinology; 1996 Jul; 137(7):3051-60. PubMed ID: 8770931
[TBL] [Abstract][Full Text] [Related]
17. Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity.
Suzuki E; Kapoor V; Cheung HK; Ling LE; DeLong PA; Kaiser LR; Albelda SM
Clin Cancer Res; 2004 Sep; 10(17):5907-18. PubMed ID: 15355924
[TBL] [Abstract][Full Text] [Related]
18. Transforming growth factor-beta1 induces desmoplasia in an experimental model of human pancreatic carcinoma.
Löhr M; Schmidt C; Ringel J; Kluth M; Müller P; Nizze H; Jesnowski R
Cancer Res; 2001 Jan; 61(2):550-5. PubMed ID: 11212248
[TBL] [Abstract][Full Text] [Related]
19. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
Uhl M; Aulwurm S; Wischhusen J; Weiler M; Ma JY; Almirez R; Mangadu R; Liu YW; Platten M; Herrlinger U; Murphy A; Wong DH; Wick W; Higgins LS; Weller M
Cancer Res; 2004 Nov; 64(21):7954-61. PubMed ID: 15520202
[TBL] [Abstract][Full Text] [Related]
20. Restoration of transforming growth factor-beta type II receptor reduces tumorigenicity in the human adrenocortical carcinoma SW-13 cell line.
Yamamoto N; Imai J; Watanabe M; Hiroi N; Sugano S; Yoshino G
Horm Metab Res; 2006 Mar; 38(3):159-66. PubMed ID: 16673206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
